C. Paul

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 815 citations

Randomised Trials, Clinical Trials, Clinical Dermatology +5

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 790 citations · Full text

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Mark Lebwohl, H. Bachelez, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2014 · 505 citations

Rheumatoid Disorder, Rheumatology, Disease Management +13

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 464 citations · Full text